No one sitting on that board did not know what was really going on, that is why we are where we are. They had to make it look okay in the real time they had nothing but corruption. Several of the board members profess honesty and integrity and capitalzing value out of small market cap companies. Looking back RS has orchestrated the fall without breaking a sweat for the real shareholders he is more concerned getting out of dodge instead of working for the shareholder. He showed that in his first interview, he never was for anybody but himself.
Roberta DeAngelis Region 3
Office of The U. S. Trustee
I suggest anyone who has issues with the current bankruptcy filing for OCZ contact the Region 3 office of Roberta DeAngelis and discuss the issues with OCZ intent and previous actions. Roberta DeAngelis does have experience in bankruptcy misconduct.
I would suggest a letter and phone call to the US trustee and lets see what happens. There is so much corruption around this company and stock, even their first exposure they see ill reasoning in the way the current agreement stands. RS, OCZ, hedge funds, RP, OCZ Board, OCZ comments, Reports have done nothing but corrupt this whole experience for any investor.
Looks like it is filling a gap the next few months will be interesting any contract wins will keep it rising. Alot of the growth is in inheriant, it does bother me this is the 2 or 3rd spin off in a few years but ITT was a big company. I do like the new divisions and hope to use them both as an aerospace and other play in my portfolio. Strong company history though would be nice for some product wins and new diversity to keep things sparking.
I do not know about a double or triple but it could settle into the 15 or so range. I did see some covering on Friday and it looked like covering and buying so you probably picked a good day. Options did not signal a bid or take out but hedge funds play with this stock once they let it get to its new range. I hope we saw the bottom around 10 25 on Friday. Only time will tell. LP was talking about a 30 to 35% growth for next year so that should put us on track for about a 50,000 bopd exit and what around 40 bopd on average sales, I do think these numbers on the exit will determine that June along with oil price naturally but KOG is pretty hedged. They usually hedge most of current production and let go new production.
The U.S. Trustee's Office on Friday targeted the auction procedures for OCZ Technology Group Inc.'s upcoming bankruptcy sale, saying they contain conditions that serve only to protect Toshiba Corp.'s $35 million stalking horse bid from rival suitors.
U.S. Trustee Roberta A. DeAngelis contended Toshiba should not receive a breakup fee and be repaid for expenses if another party trumps its offer because the tech giant would have bid for OCZ even without those provisions in place.
In March 2009, we entered into a license agreement with Amgen to expand our Precision Targeted Immunotherapy Platform by acquiring exclusive rights to CDX-301 and CD40 ligand (CD40L). CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. We may be required to pay milestones of up to $1.3 million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales to Amgen
Wght, I like arry molecues but not their efficacy. Every product I see them hit has some huge potential but they seem to hit some bumps in the road. The anti inflammatory products look interesting and if those prove fruitful it could be a steal. The problem is no one is running after the asthma to take it to the clinical and the pain drug shows some good data but it shows QT prolongation which is usually the kiss of death for chronic drugs unless the doseage if off the charts. The oncology products are licensed everywhere and could be fruitful and 520 does look very interesting. Its such a dog and pony show pipeline its hard to tell to be honest it could get taken out easily for over a billion or so if the products progress but it could also be well over 10 billion if the molecues show efficacy and that is where they continue to be more bark than bite. They do have some very interesting platform science and think its worth nippling at and for a long term hold. If you are wanting a very interesting 3 dollar stock for a long term hold I would look at Kalobiotherapeutics. The asthma drug they have looks very interesting and heading into phase 3 next year. The EPHRIN anti body are probably going to be very good products and they are going to expand that to two more indications next year. Its early for them though and they are at 52 week low so it may be worth picking up a few hundred shares for a long term hold. Overall though Arry and KBIO are both small mid term buys and long long holds both about 18 months but Arry will some data coming very soon.
Remember that line of #$%$. We are going to say less and do more. Ocz is going to focus on bringing quality products and process. This guy RS is so full of it at least you knew RP was lying to you after awhile.
This is what makes no sense one of RS first comments were on how the patents were worth in how much true talent the company has, then how in the #$%$ does he get this company in this shape without recognizing value. Actually SanDisk has the most graphene patents and IBM has a few as well. I could one of those companies easily #$%$ the patents, the problem once again RS is not telling us anything just enough to let them know how much they screwed up. I still smell a rat and RS is becoming the rat along with the board. Probably some of the best patents are probably alreadly farmed out or not settled and these guys try to show up down the road a year later. The main head on the board even teaches classes on how to gain market value out of small cap company Hmm does stealing bring that value?
They probably took money over the last few years and have stuff to hide as well with the way this is turning out. OCZ and RS have became the Enron of technology.